Synthesis of novel fluorinated bicalutamide and enzalutamide analogs.
Anti-proliferative activity in four human prostate cancer cell lines improved up to 50 folds.
Full AR antagonist effect exhibited by the new compounds.
Activity switch from partial agonist to full AR antagonist for enobosarm scaffold.
AR open conformation homology model and molecular modeling studies.